^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | eribulin liposomal (E7389-LF) (Microtubule inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of E7389 Liposomal Formulation in Subjects With Solid Tumor
Excerpt:
...Expansion-part 1 only: breast cancer with confirmed diagnosis, human epidermal growth factor (HER2) negative (immunohistochemistry [IHC] 0/1+, or fluorescence in situ hybridization [FISH] negative), prior chemotherapy of anthracycline and taxane (unless contraindicated), and up to 3 prior chemotherapy regimens to advanced or metastatic disease...
Trial ID:
Source:
Title:
346P - Phase I study of the liposomal formulation of eribulin (E7389-LF): Results from the HER2-negative breast cancer expansion
Published date:
09/14/2020
Excerpt:
Objective response rate was 35.7% (95% CI: 18.6-55.9) in all pts; in luminal BC and TNBC pts it was 42.9% (95% CI: 21.8-66.0) and 14.3% (95% CI: 0.4-57.9), respectively....E7389-LF 2.0 mg/m2 Q3W was well tolerated...and showed promising antitumor activity in pts with heavily treated, advanced, HER2-negative BC...
Trial ID:
